Research
Print page Print page
Switch language
Hvidovre Hospital - a part of Copenhagen University Hospital
Published

Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Monocyte count and soluble markers of monocyte activation in people living with HIV and uninfected controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Randomized Controlled Trial of Tesomet for Weight Loss in Hypothalamic Obesity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Oral and anal carriage of Streptococcus pneumoniae among sexually active men with HIV who have sex with men

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Incretin-based therapies, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i), have been hypothesized to exert beneficial effects on COVID-19 outcomes due to anti-inflammatory properties. In this population-based cohort study, we retrieved data from nationwide registries on all individuals diagnosed with severe acute respiratory syndrome coronavirus 2 infection up to 1 November 2020. For individuals with diabetes, we examined the impact of use of GLP-1 RAs (n = 370) and DPP-4i (n = 284) compared with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) (n = 342) on risk of hospital admission and severe outcomes. Relative risks (RRs) were calculated after applying propensity score weighted methods to control for confounding. Current users of GLP-1 RAs had an adjusted RR of 0.89 (95% confidence interval 0.34-2.33), while users of DPP-4i had an adjusted RR of 2.42 (95% confidence interval 0.99-5.89) for 30-day mortality compared with SGLT-2i use. Further, use of GLP-1 RAs or DPP-4i compared with SGLT-2i was not associated with decreased risk of hospital admission. Thus, use of incretin-based therapies in individuals with diabetes and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was not associated with improved clinical outcomes.

Original languageEnglish
Article number14329
JournalDiabetes, Obesity and Metabolism
Volume23
Issue number6
Pages (from-to)1397-1401
Number of pages5
ISSN1462-8902
DOIs
Publication statusPublished - 1 Jun 2021

Bibliographical note

Publisher Copyright:
© 2021 John Wiley & Sons Ltd

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

    Research areas

  • DPP-4 inhibitor, GLP-1 analogue, SGLT-2 inhibitor, antidiabetic drug, population study, SGLT&#8208, 1 analogue, 2 inhibitor, GLP&#8208, 4 inhibitor, DPP&#8208

ID: 61911280